Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. is a commercial-stage medical device company that develops and markets products for chronic wound care, primarily within the U.S. The company focuses on innovative cell-based technologies that utilize the human body's regenerative capacity to promote natural healing. These autologous biological therapies, derived from the patient's own body, are part of a clinical strategy aimed at improving long-term recovery in complex chronic conditions with significant unmet medical needs. The company was originally organized in 1998 as Informatix Holdings, Inc., later changing its name to Autologous Wound Therapy, Inc. in 1999, and then to Cytomedix, Inc. in 2000. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration (FDA) for the AutoloGel™ System, now known as the Aurix System, for processing peripheral blood into an autologous platelet rich plasma (PRP) for wound management. In 2010, Cytomedix acquired the Angel Whole Blood Separation System from Sorin Group USA, Inc. In 2012, Cytomedix acquired Aldagen, Inc., a privately held developmental cell-therapy company, which remains a non-operational, wholly owned subsidiary. In 2014, Cytomedix changed its name to Nuo Therapeutics, Inc. The company ceased standard operational activities in May 2019, awaiting developments regarding Medicare coverage for Aurix. In April 2021, the Centers for Medicare & Medicaid Services (CMS) issued a favorable National Coverage Determination (NCD) for autologous PRP products, and the company restarted business activities in October 2021. The company's principal offices are located in Houston, Texas.